Document is current
Any future updates will be listed below
-
Authors
Lo, Grace H. https://orcid.org/0000-0003-3142-1839
Richard, Michael J. https://orcid.org/0000-0001-9617-9989
Cauley, Jane A. https://orcid.org/0000-0003-0752-4408
Driban, Jeffrey B. https://orcid.org/0000-0001-6098-4273
Strayhorn, Michael
MacKay, James https://orcid.org/0000-0001-7558-3800
Harkey, Matthew S. https://orcid.org/0000-0002-3480-3173
McAlindon, Timothy E. https://orcid.org/0000-0002-5031-1021
Jansen, Mary
Green, Stephanie
White, Donna L. https://orcid.org/0000-0003-0297-2949
Kwoh, C. Kent https://orcid.org/0000-0001-5937-550X
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R03AR069323)
VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413)
National Institutes of Health (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262, 5 TL1 TR 1454-3)
Merck
Novartis Pharma
GlaxoSmithKline
Pfizer
- License Information
-
More Information
Article History
Received: 31 January 2022
Accepted: 9 March 2022
First Online: 23 April 2022
Declarations
:
: The authors state they have no conflict of interest with regard to this work. The authors of this study have full control of all primary data and they agree to allow the journal to review the data if requested.
: All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The Institutional Review Boards at the University of Pittsburgh (PRO16040088) and Baylor College of Medicine (H-3782) approved this study.
: All individual participants gave their informed consent prior to their inclusion in the study.
